{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:41:14Z","timestamp":1776087674598,"version":"3.50.1"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p>Inflammatory breast carcinoma (IBC) is an aggressive form of breast cancer. Prior studies have reported the presence of lobular histology in a small percentage of tumors from patients with IBC. However, the significance of these lobular features in IBC has yet to be fully characterized. We performed a comprehensive retrospective review of patients with IBC with lobular features (IBC-LF) to evaluate their clinicopathologic features. Our IBC program registry included 524 patients over a 20-year interval, 74 (14%) of whom had lobular features. Pathology material was available for review for 28 patients, and these patients were the focus of this study. On the basis of study criteria, 12 were classified as pure invasive lobular carcinoma (ILC) and 16 as invasive carcinoma with ductal and lobular features (IDLC). All were histologic grade 2-3. Receptor profiles included ER+\/HER2- in 14\/28 (50%), ER-\/HER2- in 7\/28 (25%), and ER(+\/-)\/HER2- in 7\/28 (25%). In the 12 cases of pure ILC, 11 showed variant morphologic features, including 6 (50%) with pleomorphic apocrine features, 3 (25%) with a solid growth pattern, 1 with signet ring-cell, and 1 with histiocytoid features. All ILC cases showed negative or aberrant staining for E-cadherin, p120, and beta-catenin on immunohistochemical studies. Dermal lymphovascular invasion was seen in 13 (46.4%) cases, while direct dermal invasion was seen in 14 (50%) cases. Our study confirms that IBC may arise from pure ILC, with negative E-cadherin expression, and usually with variant morphology. This is the first study to detail the morphologic and immunophenotypic characteristics of IBC-LF.<\/jats:p>","DOI":"10.1097\/pas.0000000000002446","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T08:00:10Z","timestamp":1751529610000},"page":"882-889","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["The Clinicopathologic Features of Inflammatory Breast Carcinoma (IBC) With Lobular Features"],"prefix":"10.1097","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2596-2604","authenticated-orcid":false,"given":"S. Emily","family":"Bachert","sequence":"first","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, MA"},{"name":"Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison M.","family":"Onken","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, MA"},{"name":"Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison S.","family":"Cleary","sequence":"additional","affiliation":[{"name":"The University of Utah\/ARUP Laboratories, Salt Lake City, UT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faina","family":"Nakhlis","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, MA"},{"name":"Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer R.","family":"Bellon","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, MA"},{"name":"Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth A","family":"Overmoyer","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA"},{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filipa","family":"Lynce","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA"},{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth T.","family":"Harrison","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, MA"},{"name":"Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"R1-20250815","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/bcr3571","article-title":"The Third International Inflammatory Breast Cancer Conference","volume":"15","author":"van Golen","year":"2013","journal-title":"Breast Cancer Res"},{"key":"R2-20250815","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.7150\/jca.21200","article-title":"Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10(th) Anniversary Conference","volume":"8","author":"Woodward","year":"2017","journal-title":"J Cancer"},{"key":"R4-20250815","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10549-021-06434-x","article-title":"Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research","volume":"192","author":"Jagsi","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"R5-20250815","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.ejso.2018.04.001","article-title":"Inflammatory breast cancer: the pathologists\u2019 perspective","volume":"44","author":"Cserni","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"R6-20250815","first-page":"5079","article-title":"A novel human xenograft model of inflammatory breast cancer","volume":"59","author":"Alpaugh","year":"1999","journal-title":"Cancer Res"},{"key":"R7-20250815","first-page":"5231","article-title":"An intact overexpressed E-cadherin\/alpha,beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma","volume":"61","author":"Tomlinson","year":"2001","journal-title":"Cancer Res"},{"key":"R8-20250815","doi-asserted-by":"crossref","first-page":"e0145534","DOI":"10.1371\/journal.pone.0145534","article-title":"Inflammatory breast cancer: a distinct clinicopathological entity transcending histological distinction","volume":"11","author":"Raghav","year":"2016","journal-title":"PLoS One"},{"key":"R9-20250815","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0039-6109(16)40383-X","article-title":"Inflammatory carcinoma of the breast","volume":"54","author":"Robbins","year":"1974","journal-title":"Surg Clin North Am"},{"key":"R10-20250815","doi-asserted-by":"crossref","first-page":"211","DOI":"10.5152\/ejbh.2018.4170","article-title":"The impact of subtype distribution in inflammatory breast cancer outcome","volume":"14","author":"\u00c7akar","year":"2018","journal-title":"Eur J Breast Health"},{"key":"R11-20250815","first-page":"35","article-title":"Molecular subtypes in patients with inflammatory breast cancer; a single center experience","volume":"20","author":"Kertmen","year":"2015","journal-title":"J BUON"},{"key":"R12-20250815","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.breast.2003.08.004","article-title":"High incidence of HER-2 positivity in inflammatory breast cancer","volume":"13","author":"Parton","year":"2004","journal-title":"Breast"},{"key":"R13-20250815","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1053\/j.semdp.2009.12.009","article-title":"Lobular breast carcinoma and its variants","volume":"27","author":"Rakha","year":"2010","journal-title":"Semin Diagn Pathol"},{"key":"R15-20250815","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1477-7819-6-10","article-title":"Skin invasion and prognosis in node negative breast cancer: a retrospective study","volume":"6","author":"Tada","year":"2008","journal-title":"World J Surg Oncol"},{"key":"R16-20250815","first-page":"99","article-title":"Invasive lobular carcinoma of the breast: role of endothelial lymphatic marker D2-40","volume":"38","author":"Laser","year":"2008","journal-title":"Ann Clin Lab Sci"},{"key":"R17-20250815","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.cell.2015.09.033","article-title":"Comprehensive molecular portraits of invasive lobular breast cancer","volume":"163","author":"Ciriello","year":"2015","journal-title":"Cell"},{"key":"R18-20250815","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/jcp.46.2.189-b","article-title":"Method for grading breast cancer","volume":"46","author":"Elston","year":"1993","journal-title":"J Clin Pathol"},{"key":"R19-20250815","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP Guideline Update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"key":"R20-20250815","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"R21-20250815","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J Clin Oncol"},{"key":"R22-20250815","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1097\/PAS.0b013e3181f01916","article-title":"Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast","volume":"34","author":"Rakha","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"R23-20250815","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/01.pas.0000213386.63160.3f","article-title":"Lobular versus ductal breast neoplasms: the diagnostic utility of p120 catenin","volume":"31","author":"Dabbs","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"R24-20250815","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/his.12869","article-title":"E-cadherin immunohistochemistry in breast pathology: uses and pitfalls","volume":"68","author":"Canas-Marques","year":"2016","journal-title":"Histopathology"},{"key":"R25-20250815","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/modpathol.3880334","article-title":"Persistent E-cadherin expression in inflammatory breast cancer","volume":"14","author":"Kleer","year":"2001","journal-title":"Mod Pathol"},{"key":"R26-20250815","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/PAS.0b013e3182918a2b","article-title":"Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry","volume":"37","author":"Dabbs","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"R27-20250815","doi-asserted-by":"crossref","first-page":"100497","DOI":"10.1016\/j.modpat.2024.100497","article-title":"Integration of pathological criteria and immunohistochemical evaluation for invasive lobular carcinoma diagnosis: recommendations from the European lobular breast cancer consortium","volume":"37","author":"De Schepper","year":"2024","journal-title":"Mod Pathol"},{"key":"R28-20250815","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejca.2007.10.009","article-title":"Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes","volume":"44","author":"Rakha","year":"2008","journal-title":"Eur J Cancer"},{"key":"R29-20250815","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s10549-012-2002-z","article-title":"Invasive lobular breast cancer: subtypes and outcome","volume":"133","author":"Iorfida","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"R30-20250815","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/0046-8177(92)90321-S","article-title":"Pleomorphic lobular carcinoma of the breast: an aggressive tumor showing apocrine differentiation","volume":"23","author":"Eusebi","year":"1992","journal-title":"Hum Pathol"},{"key":"R31-20250815","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/00000478-199001000-00002","article-title":"Prognosis in infiltrating lobular carcinoma. An analysis of \u201cclassical\u201d and variant tumors","volume":"14","author":"DiCostanzo","year":"1990","journal-title":"Am J Surg Pathol"},{"key":"R32-20250815","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1097\/00000478-200012000-00009","article-title":"Pleomorphic lobular carcinoma: morphology, immunohistochemistry, and molecular analysis","volume":"24","author":"Middleton","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"R33-20250815","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00432-006-0140-6","article-title":"Dominant-negative E-cadherin inhibits the invasiveness of inflammatory breast cancer cells in vitro","volume":"133","author":"Dong","year":"2007","journal-title":"J Cancer Res Clin Oncol"},{"key":"R34-20250815","first-page":"3903","article-title":"E-cadherin accumulation within the lymphovascular embolus of inflammatory breast cancer is due to altered trafficking","volume":"30","author":"Ye","year":"2010","journal-title":"Anticancer Res"},{"key":"R35-20250815","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1038\/onc.2012.180","article-title":"The genesis and unique properties of the lymphovascular tumor embolus are because of calpain-regulated proteolysis of E-cadherin","volume":"32","author":"Ye","year":"2013","journal-title":"Oncogene"},{"key":"R36-20250815","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.clbc.2012.04.005","article-title":"Evaluation of lymphangiogenic factors, vascular endothelial growth factor D and E-cadherin in distinguishing inflammatory from locally advanced breast cancer","volume":"12","author":"Levine","year":"2012","journal-title":"Clin Breast Cancer"},{"key":"R37-20250815","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.3390\/ijms22031275","article-title":"PLEKHA7, an apical adherens junction protein, suppresses inflammatory breast cancer in the context of high E-cadherin and p120-catenin expression","volume":"22","author":"Pence","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R38-20250815","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1002\/cncr.11332","article-title":"Role of E-cadherins in development of lymphatic tumor emboli","volume":"97","author":"Gupta","year":"2003","journal-title":"Cancer"},{"key":"R39-20250815","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/sj.bjc.6600807","article-title":"Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression","volume":"88","author":"Colpaert","year":"2003","journal-title":"Br J Cancer"},{"key":"R40-20250815","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13058-015-0519-x","article-title":"Invasive lobular carcinoma of the breast: morphology, biomarkers and \u2018omics","volume":"17","author":"McCart Reed","year":"2015","journal-title":"Breast Cancer Res"},{"key":"R41-20250815","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/path.4668","article-title":"An epithelial to mesenchymal transition programme does not usually drive the phenotype of invasive lobular carcinomas","volume":"238","author":"McCart Reed","year":"2016","journal-title":"J Pathol"},{"key":"R42-20250815","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/path.5040","article-title":"Mixed ductal-lobular carcinomas: evidence for progression from ductal to lobular morphology","volume":"244","author":"McCart","year":"2018","journal-title":"J Pathol"},{"key":"R43-20250815","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","article-title":"Epithelial-mesenchymal transitions in development and disease","volume":"139","author":"Thiery","year":"2009","journal-title":"Cell"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002446","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T04:00:16Z","timestamp":1755230416000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002446","relation":{},"ISSN":["0147-5185","1532-0979"],"issn-type":[{"value":"0147-5185","type":"print"},{"value":"1532-0979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]}}}